Influenza A is a subtype of influenza virus that circulates in humans and contributes to seasonal epidemics; currently circulating human subtypes include A(H1N1) and A(H3N2). Type A influenza viruses are also the only influenza type known to have caused pandemics.
The CDC reported six new influenza-associated pediatric deaths in Week 6 of 2026, bringing the 2025-2026 U.S. season total to 71. About 90% of deaths with known vaccination status were in children not fully vaccinated.
Vir Biotechnology is set to report Q4 2025 earnings on Feb 23, 2026, with analysts expecting revenue of $19.91-$23.18 million and a loss of $0.41-$0.50 per share, marking a 61% year-over-year revenue increase.
Moderna announced the FDA will consider approving its mRNA-based flu vaccine for older adults after resolving a dispute over clinical trial design. The vaccine showed 34.5% higher efficacy than standard flu shots in trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07430410 |
Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test |
NOT_YET_RECRUITING | NA |
| NCT07330986 |
Influenza A-associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit in China |
COMPLETED | |
| NCT07314905 |
Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07308158 |
Covid Flu A/B and RSV 4 in 1 Diagnostic Test |
COMPLETED | |
| NCT07229820 |
Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07229807 |
Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07217639 |
Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings |
NOT_YET_RECRUITING | NA |
| NCT07190131 |
Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test |
COMPLETED | |
| NCT07128615 |
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT06800950 |
Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine |
NOT_YET_RECRUITING | PHASE3 |
